NDA 6931, held by Glaxosmithkline. Decamethonium Bromide.
As of Nov 13, 2026, NDA 6931 (Syncurine), held by Glaxosmithkline, was not approved, with 2 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Syncurine1MG/ML ยท injectable;injection | Decamethonium Bromide | Discontinued |
| Jun 26, 1979 | Supplement 3Manufacturing | Approved | None posted |
| May 21, 1975 | Supplement 1Labeling | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
